ID   T1889
AC   CVCL_D024
SY   TC1889; T-1889; 1889c
DR   Cosmic; 1498256
DR   GEO; GSM577204
DR   Wikidata; Q54971425
RX   PubMed=18360827;
RX   PubMed=34781947;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met246Ile (c.738G>T); ClinVar=VCV000968639; Zygosity=Homozygous (PubMed=34781947).
CC   Omics: Variations; Array-based CGH.
DI   NCIt; C35718; Thymic undifferentiated carcinoma
DI   ORDO; Orphanet_99868; Thymic carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 10
//
RX   PubMed=18360827; DOI=10.1002/ijc.23335;
RA   Ehemann V., Kern M.A., Breinig M., Schnabel P.A., Gunawan B.,
RA   Schulten H.-J., Schlaeger C., Radlwimmer B., Steger C.M.,
RA   Dienemann H., Lichter P., Schirmacher P., Rieker R.J.;
RT   "Establishment, characterization and drug sensitivity testing in
RT   primary cultures of human thymoma and thymic carcinoma.";
RL   Int. J. Cancer 122:2719-2725(2008).
//
RX   PubMed=34781947; DOI=10.1186/s12916-021-02158-3; PMCID=PMC8594228;
RA   Muller D., Mazzeo P., Koch R., Bosherz M.-S., Welter S.,
RA   von Hammerstein-Equord A.F., Hinterthaner M., Cordes L., Belharazem D.,
RA   Marx A., Strobel P., Kuffer S.;
RT   "Functional apoptosis profiling identifies MCL-1 and BCL-xL as
RT   prognostic markers and therapeutic targets in advanced thymomas and
RT   thymic carcinomas.";
RL   BMC Med. 19:300.1-300.14(2021).
//